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The scientific advances done in BS since the first cases were reported and a better characterization of the patients has led to changes in its definition. Furthermore, we believe that the incorporation of new clinical and genetic data will lead to a better definition and characterization of the syndrome in the future.
The initial definition
Brugada syndrome was initially described in 1992 in an article published in the Journal of the American College of Cardiology.
2 It presented a series of eight patients who displayed a right bundle branch block, a persistent ST elevation of at least 0.1 mV in the right precordial leads (V1 to V2-V3) and repetitive resuscitated SCD ( Figure 1) . This was the first definition of BS, for several years known as the syndrome of 'right bundle branch block, persistent ST segment elevation and sudden death'. In 1996, several reports, mainly coming from Japan, started calling the syndrome Brugada syndrome. 3 This characteristic ECG pattern had occasionally appeared in previous literature but its association with SCD as a differentiated syndrome had not been stablished. In 1953, an ECG displaying the characteristic pattern was published 4 and in 1989 it appeared amongst others in a report of six cases of ventricular fibrillation in young patients. 5 However, in contrast to the report in JACC, their patients had structural heart disease with no evidence of a hereditary disorder.
After the publication of this initial report, a lively discussion quickly developed. Concerns about its true nature and being an independent entity were common. If even nowadays the pathophysiology of the syndrome remains to be fully understood, 6 at that moment many suggested that the syndrome was related to myocarditis, right ventricular dysplasia, other forms of cardiomyopathies, long QT or simply a normal variant. It was not until 1998, when the first genetic basis of the syndrome was stablished, 7 that the acceptance of an independent disease was widely accepted ( 
The first consensus
In 2002, a consensus document for the diagnosis of BS was published. 8 It attempted to summarize the scientific knowledge gathered since the initial description of the syndrome, 10 years before. An operative definition of the syndrome was clearly stated. The diagnostic ECG pattern was described as a prominent coved STsegment elevation displaying J wave amplitude or ST-segment elevation >2 mm at its peak, followed by a negative T-wave, with little or no isoelectric separation in right precordial leads (V1 to V3).
Three different ECG patterns were described at this moment ( Figure 2) . Type 1 is the one described above and the only one that establishes the diagnosis. Type 2 was defined as a high take-off of STsegment elevation, but J wave amplitude (2 mm) gives rise to a gradually descending ST-segment elevation (remaining 1 mm above the baseline), followed by a positive or biphasic T-wave that results in a saddle back configuration. Type 3 is a right precordial ST-segment elevation of <1 mm of saddle back type, coved type, or both.
Even that this definition was formulated 15 years ago, the description of the type 1 ECG pattern remains unchanged nowadays. Nevertheless, as will be discussed later, some aspects considered in this consensus document are no longer up to date. At that moment, the V3 lead was considered as a useful lead for the diagnosis and even, in selected patients, the recording of leads V3R and V4R was thought useful. We nowadays know that the ECG pattern should be interpreted only in V1 and V2 as the other leads offer no further advanatge. 9 The fact that the diagnostic type 1 ECG pattern can be present intermittently is of great importance. Furthermore, the typical electrocardiographic pattern might experience spontaneous variations, in both morphology and degree of elevation of the ST segment. [10] [11] [12] In addition to spontaneous fluctuations, many factors and drugs influence the elevation. 3, 13 Some patients might only present the diagnostic ECG pattern under the effect of sodium channel blockers such as ajmaline, flecainide, or procainamide. Use of sodium channel blockers to unmask the type 1 diagnostic pattern became generalized after 2000.
14 Despite that current clinical guidelines do not make specific statement of which should be chosen, probably ajmaline is the most efficient one. Initial reports suggested a similar effect of the different drugs in unmasking the Brugada type 1 pattern.
14 Nevertheless, further ones demonstrated a superiority of ajmaline. Failure of flecainide in unmasking the Brugada pattern could be up to 30%. 15 The use of these drugs is directly linked to the pathophysiology of the syndrome, the alteration of the sodium channels. It is of importance that while knowledge on BS has increased and more patients have been diagnosed, also the clinical presentation of patients with BS has changed. Nowadays most patients are diagnosed while still they are asymptomatic and many do not present the characteristic ECG pattern spontaneously, but after a pharmacologic challenge. 16 This is the result of a greater clinical suspicion of the disease (for instance in patients with syncope or idiopathic atrial fibrillation) and an intensive screening of family members of patients diagnosed with BS or who suffered SCD of unknown cause. Interestingly, this consensus recognizes that the pattern could be recorded not only in the classical V1 and V2 lead positioning, in the 4th intercostal space, but also in higher intercostal spaces. We now know that ventricular arrhythmias in BS are originated in the right ventricular outflow tract. 17 Use of higher intercostal leads increases the sensitivity of the ECG to detect the type 1 pattern. The anatomical explanation for this has been recently described. 18 Its importance relies on the fact that prognosis of patients is irrespective of the positioning of the lead where the type 1 pattern is recognized.
Contemporary definition
In 2013, a new expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes was published. 19 More than 10 years had passed since the first one and great progress had been made since then ( Figure 3) . A better knowledge of the pathophysiology and risk stratification of BS was available at that moment. As a result, definition of BS had to be updated. The BS definition established in this consensus is the one we use nowadays. This definition is also present in the 2015 European Society of Cardiology guidelines for ventricular arrhythmias and the prevention of SCD. 20 Brugada syndrome is diagnosed in patients with ST-segment elevation with type 1 morphology > _2 mm in > _1 lead in the right precordial leads V1, V2, positioned in the 2nd, 3rd, or 4th intercostal space occurring either spontaneously or after provocative drug test with intravenous administration of class I antiarrhythmic drugs.
Two important aspects must be highlighted. First, only the type 1 ECG pattern is diagnostic, either spontaneously or after a drug challenge. A type 2 ECG pattern may raise the suspicion of BS but the diagnosis can only be made when the type 1 pattern appears or is induced by sodium channel blockers. This fact has also prognosis significance as those patients that do not display the type 1 spontaneously have a better outcome, but arrhythmic events and SCD can still occur. 21 Interestingly, nowadays the type 3 ECG pattern is no longer considered in BS. 22 Second, the presence of a type 1 ECG pattern in one single lead, V1 or V2, is enough for the diagnosis. Until now it was necessary to find the pattern in at least two leads and V3 was considered useful for . The scientific progress achieved during these years led to the appearance of 'overlapping syndromes'. Brugada syndrome and right ventricular dysplasia present some overlapping characteristics. Mild fibrosis in the RVOT and even fibro-fatty infiltration has been reported in BS but its presence is not universal. 23 Recently, mutations in the PKP-2 gene, related to desmosomes have been identified in BS. 24, 25 Desmosomal mutations are known to cause arrhythmogenic cardiomyopathy and, interestingly, also sodium channel dysfunction. Though the two syndromes are separate identifiable clinical entities, they might represent in certain cases 'bookends' of a spectrum of clinical manifestations that vary depending on the effect that a particular mutation has on the connexome as a whole. 26 Furthermore, we know that sodium channel interacting partners are proteins that can interact and modulate the expression and/or function of sodium channels. They might be involved in some case of BS. Amongst them Plakophilin-2 and Connexin-43 might be relevant. 27, 28 The concept of Brugada phenocopies has recently aroused. They are clinical entities that present identical ECG patterns to BS but are elicited by other circumstances. They form a group of heterogeneous conditions that are sometimes difficult to differentiate from true BS. Entities that might induce a Brugada phenocopy include metabolic conditions, mechanical compression, myocardial ischaemia, pulmonary embolism, and myocardial and pericardial disease amongst others. 29 Differential diagnosis with some clinical entities can be challenging. Doubts can arise when dealing with patients with right bundle branch block, athletes and, as mentioned before, with arrhytmogenic ventricular dysplasia. A careful study of the ECG might help. Specifically, in right bundle branch block, the ST segment is not elevated in the right precordial leads, the terminal wave is synchronous with the broad S wave observed in leads I and V6, and the QRS is wider than in BS. As opposed to athletes' ECG, BS Type 1 ECG pattern depicts an ST segment clearly elevated and down-sloping, usually with no visible r 0 . In arrhytmogenic right ventricular dysplasia, atypical right bundle branch block morphologies have been shown, with a 'plateau' in the R wave in lead V1. The ST segment is at times elevated but does not usually mimic type 2 Brugada pattern. Moreover, T waves are more frequently negative in many precordial leads (V1 to V3-V5) and ECG pattern is fixed with no spontaneous changes in morphology or ST elevation. 22 Interestingly, vectocardiography might have a role in the diagnosis of BS. 30 It can help in the differential diagnosis of BS with early repolarization syndromes or right bundle branch block.
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The future of Brugada syndrome
Twenty-five years ago, when BS was first described, great controversy surrounded the syndrome, we lacked knowledge about it and still today many aspects of the syndrome have not been fully elucidated. The scepticism has largely, though not entirely, abated as BS has become an everyday cardiological problem to be considered in patients and families with ventricular arrhythmias, syncope, and a structurally normal heart, but also in patients with isolated atrial fibrillation, that may be the first manifestation of BS. 33 Especially during the first years, the absence of a clear pathophysiologic mechanism, raised doubts regarding its consideration as an independent entity. It was in 1998, when the first genetic evidence of the syndrome was described when most concerns were cleared. Numerous pathogenic mutations in several genes have been found that encode for subunits of cardiac sodium, potassium, and calcium channels, as well as genes involved in the regulation of these channels. [34] [35] [36] However, many of these identified gene mutations are probably not directly responsible for the disease or at least not alone. The use of genetic testing in cardiology practice has become widespread in the recent years owing to advances in next-generation sequencing technology. Given the complexity and limitations of genetic testing, however, commercially available test kits might only serve to complicate the diagnostic procedure for the practicing clinician. To date, genetic screening is recommended only for family members of BS probands who have been successfully genotyped; genetic testing is useful in these individuals for advancing research, and for establishing genotype-phenotype relationships and identifying family members who might be at risk. 37 Still now, only the presence of a type 1 BS pattern stablishes the diagnosis. Despite all the genetic information available we have not been able to transfer its usefulness to the diagnostic process. The wide spectrum of the severity of the electrocardiographic and clinical manifestations of BS might correlate with the existence of a wide array of underlying genetic and cellular abnormalities of the myocardium. Therefore, the typical Brugada ECG pattern might be the result of a combination of mechanisms.
A better understanding of the pathophysiology and the genetic basis of the syndrome might let us to redefine the syndrome and stablish new diagnostic criteria, besides a single ECG pattern, the STsegment elevation. Twenty-five years ago, the syndrome was defined by this ECG characteristic. This definition has been useful so far, however it has limitations. Despite all the genetic knowledge that is now available, some patients remain difficult to characterize. In the same family, a given mutation will result in BS in some individuals whilst, in others, it might present as sinus node dysfunction or conduction abnormalities. 38 With our current definition, these syndromes are not yet well characterized. Furthermore, arrhythmic risk might vary amongst patients with the same mutation. The interactions are yet to be clarified. In the future, we might be able to better stablish the diagnostic ECG pattern (ST elevation, sinus node dysfunction, or conduction abnormalities) based on the genetic information. Further genetic characterization of the syndrome might not only lead to a better understanding of the underlying pathophysiology and arrhythmic risk stratification but also to the clarification of these overlap syndromes and a new whole definition process.
Conclusion
The BS was described initially as the syndrome of 'right bundle branch block, persistent ST elevation and SCD'. We now know that patients do not have right bundle branch block, ST elevation is no necessarily persistent, and SCD is not the only manifestation of the disease. A reverse definition process, from genetics to ECG, might be about to start.
